Needham Maintains Buy on Apellis Pharmaceuticals, Lowers Price Target to $60
Portfolio Pulse from Benzinga Newsdesk
Needham analyst Joseph Stringer has maintained a 'Buy' rating on Apellis Pharmaceuticals (NASDAQ:APLS) but lowered the price target from $110 to $60.

July 31, 2023 | 4:40 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Apellis Pharmaceuticals' price target has been lowered from $110 to $60 by Needham, though the 'Buy' rating is maintained.
The lowering of the price target by Needham indicates a potential decrease in the stock's value. However, the maintained 'Buy' rating suggests that the stock is still expected to perform well in the long term. This could lead to short-term negative impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100